Search
Gene-Editing Therapy Demonstrates Success in Lowering Cholesterol Levels
2025-04-23 /
Read about 0 minute
Author：小编
Boston-headquartered Verve Therapeutics has unveiled promising results from clinical trials of its CRISPR gene-editing therapy, Verve-102. This innovative treatment effectively lowered cholesterol levels in 14 participants by altering the DNA of liver cells, without reporting any significant side effects. Inspired by individuals with PCSK9 gene mutations who naturally exhibit low cholesterol levels, a single administration of Verve-102 could offer lifelong benefits. This groundbreaking achievement paves the way for novel treatment avenues for patients suffering from hypercholesterolemia.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
